Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment 

Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients

Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease 

Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo 

In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival

Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care  

Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer 

Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context

Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit 

Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.